23 completed. 23 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 23 | Completed 23 |
| Phase 2 | 8 | Completed 8 |
Follow Craniofacial Abnormalities: new trials by email Literature Review of Craniofacial Abnormalities trials Research Report on Craniofacial Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer Erdafitinib Intravesical Delivery System - Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor | Phase 1 | Completed | Janssen Pharmaceutical K.K. | 5 | 2023-03-03 | 2026-11-03 |
| A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC ERAS-007, ERAS-601, Osimertinib - Advanced Non-squamous Non-small-cell Lung Cancer | Phase 1 | Completed | Erasca, Inc. | 24 | 2021-09-02 | 2023-07-25 |
| A Dose Escalation/Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors ERAS-601, Cetuximab, Pembrolizumab - Advanced or Metastatic Solid Tumors | Phase 1 | Completed | Erasca, Inc. | 90 | 2020-12-15 | 2026-09-16 |
| A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer E7090, Fulvestrant, Exemestane - Breast Neoplasms | Phase 1 | Completed | Eisai Co., Ltd. | 51 | 2020-10-09 | 2026-07-17 |
| A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China JAB-3312 - Non-small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Completed | Allist Pharmaceuticals, Inc. | 17 | 2020-07-14 | 2025-05-20 |
| RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors RLY-1971 - Solid Tumor, Unspecified, Adult | Phase 1 | Completed | Hoffmann-La Roche | 56 | 2020-02-04 | 2023-01-31 |
| A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors JAB-3312 - Non-small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Completed | Jacobio Pharmaceuticals Co., Ltd. | 40 | 2019-09-26 | 2025-12-29 |
| Derazantinib and Atezolizumab in Patients With Urothelial Cancer Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg - Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | Basilea Pharmaceutica | 95 | 2019-08-02 | 2023-10-13 |
| Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC RMC-4630, Cobimetinib, Drug: Osimertinib - Solid Tumor | Phase 1 / Phase 2 | Completed | Revolution Medicines, Inc. | 113 | 2019-07-02 | 2023-06-26 |
| A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China JAB-3068 - Non-small Cell Lung Cancer, Head and Neck Cancer | Phase 1 / Phase 2 | Completed | Jacobio Pharmaceuticals Co., Ltd. | 126 | 2018-11-20 | 2024-09-25 |
| A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors JAB-3068 - Non-small Cell Lung Cancer, Head and Neck Cancer | Phase 1 | Completed | Jacobio Pharmaceuticals Co., Ltd. | 38 | 2018-04-23 | 2024-12-16 |
| A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102) Pemigatinib - Solid Tumors | Phase 1 | Completed | Incyte Corporation | 44 | 2017-08-01 | 2020-05-29 |
| Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions NFC-1 - 22q11.2 Deletion Syndrome | Phase 1 | Completed | Aevi Genomic Medicine, LLC, a Cerecor company | 2 | 2016-11-28 | 2022-03-25 |
| Botulinum Toxin to Improve Cosmesis of Primary Cleft Lip Repair Botulinum Toxin Type A, Normal Saline Injection - Cleft Lip, Scarring | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center, Houston | 30 | 2015-12-01 | 2021-11-03 |
| Description of Pain in Pediatric Patients With Cleft Lip and Palate Undergoing Alveolar Grafting Using Two Surgical Strategies: Stem Cells and Autogenous Iliac Crest Bone (Pain Evaluation in Children Undergoing Alveolar Grafting: Stem Cells vs. Iliac Crest Bone) Autogenous Iliac Crest Bone Grafting, Bioengineered Alveolar Grafting (SHED + Scaffold) - Clift Lip, Cleft Palate | Phase 1 / Phase 2 | Completed | Hospital Sirio-Libanes | 20 | 2015-03-01 | 2026-07-29 |
| Phase 1b Trial of BGJ398/BYL719 in Solid Tumors BGJ398, BYL719 - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 62 | 2013-10-01 | 2020-12-09 |
| Applicability Clinic of Cement Portland Structural White in Endodontic Surgery ENDODONTIC SURGERY - Mandibular Hypoplasia | Phase 1 / Phase 2 | Completed | Universidade do Vale do Sapucai | 12 | 2013-02-01 | 2015-06-18 |
| Cell Therapy for Craniofacial Bone Defects Ixmyelocel-T, Autogenous Bone Grafting - Cleft Palate, Trauma | Phase 1 / Phase 2 | Completed | University of Michigan | 18 | 2012-08-01 | 2017-05-04 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma JNJ-42756493: Part 1, JNJ-42756493: Part 2, JNJ-42756493: Part 3 - Tumor or Lymphoma | Phase 1 | Completed | Janssen Research & Development, LLC | 188 | 2012-06-15 | 2025-02-03 |
| Amicar Pharmacokinetics of Children Having Craniofacial Surgery Epsilon-Aminocaproic Acid - Craniosynostosis | Phase 1 | Completed | Paul Stricker | 18 | 2009-05-01 | 2012-11-01 |
Showing 20 of 23. Sign in to see all of them.
Noonan Syndrome (8) · Carcinoma, Non-Small-Cell Lung (7) · Acrocephalosyndactylia (6) · Colorectal Neoplasms (6) · Squamous Cell Carcinoma of Head and Neck (5) · Breast Neoplasms (4) · DiGeorge Syndrome (4) · Neoplasms (4) · Cleft Palate (3) · Thymic aplasia (3) · Urinary Bladder Neoplasms (3) · Carcinoma, Pancreatic Ductal (2) · Cleft Lip (2) · Esophageal Neoplasms (2) · Esophageal Squamous Cell Carcinoma (2)
Congenital Abnormalities (23) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (23) · Musculoskeletal Abnormalities (23) · Musculoskeletal Diseases (23) · Cardiovascular Abnormalities (12) · Cardiovascular Diseases (12) · Heart Defects, Congenital (12) · Heart Diseases (12) · Neoplasms by Site (11) · Skin and Connective Tissue Diseases (10) · Neoplasms (9) · Bone Diseases (8) · Connective Tissue Diseases (8) · Neoplasms by Histologic Type (8)
Thymus Extracts (2) · osimertinib (2) · Alpelisib (1) · Aminocaproic Acid (1) · Antilymphocyte Serum (1) · Blood Specimen Collection (1) · Botulinum Toxins, Type A (1) · Cetuximab (1) · Cyclosporine (1) · Cyclosporins (1) · Daclizumab (1) · Drug Implants (1) · Fulvestrant (1) · Methylprednisolone (1) · Mycophenolic Acid (1)
Jacobio Pharmaceuticals Co., Ltd. (3) · Sumitomo Pharma Switzerland GmbH (3) · Erasca, Inc. (2) · Aevi Genomic Medicine, LLC, a Cerecor company (1) · Allist Pharmaceuticals, Inc. (1) · Basilea Pharmaceutica (1) · Eisai Co., Ltd. (1) · Hoffmann-La Roche (1) · Hospital Sirio-Libanes (1) · Incyte Corporation (1) · Janssen Pharmaceutical K.K. (1) · Janssen Research & Development, LLC (1) · Novartis Pharmaceuticals (1) · Paul Stricker (1) · Revolution Medicines, Inc. (1)
United States (16) · Australia (3) · France (3) · Japan (3) · South Korea (3) · Spain (3) · Canada (2) · China (2) · Germany (2) · Italy (2) · Switzerland (2) · Austria (1) · Belgium (1) · Brazil (1) · Czechia (1)
M. Louise Markert, MD, PhD (3) · Yuankai Shi, MD (2) · Daniela Francescato Veiga (1) · Darnell Kaigler, DDS, PhD (1) · Ekaterine Asatiani, MD (1) · Jaecel O Shah, MD (1) · Joyce Antal (1) · Les Brail, PhD (1) · Paul Stricker, MD (1)
PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 20236866, PMID 15100156, PMID 17284531, PMID 23607606, PMID 15100681, PMID 18155964, PMID 18333898, PMID 20443823, PMID 20978268, PMID 21120277, PMID 22590644, PMID 23117614, PMID 26324363, PMID 31088831, PMID 31280362, PMID 35690720, PMID 37120522, PMID 38627238
K12HD043494 (3), R01AI047040 (3), R01AI054843 (3), R56AI047040 (2), 2019 (1)